First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients

Pancreatic Cancer Clinical Trial

Official title:

A Multicenter,Open-label,Exploratory Study of QL1706 Plus Nab-paclitaxel and Gemcitabine With or Without Bevacizumab as First-line Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06313970
• Other study ID #: QLMA-PC-IIT-001
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: April 15, 2024
• Est. completion date: April 15, 2026

Study information

• Verified date: March 2024
• Source: Fudan University
• Contact: Si Shi, MD
• Phone: +86-021-64179375
• Email: shisi[@]fudanpci.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, open-label, exploratory study to evaluate the efficacy and safety of QL1706 plus nab-paclitaxel and gemcitabine with or without bevacizumab as first-line treatment in patients with unresectable locally advanced or metastatic pancreatic cancer

Description:

This study is an open, multicenter, exploratory clinical trial designed to evaluate the efficacy and safety of QL1706 in combination with albumin paclitaxel and gemcitabine with or without bevacizumab for the first-line treatment of patients with unresectable locally advanced or metastatic pancreatic cancer. The study was conducted in patients with unresectable locally advanced or metastatic pancreatic cancer who had not received prior systemic therapy. Subjects sign informed consent, undergo a screening period of examination and evaluation, which lasts for 21 days, and those who meet the entry criteria enter the treatment period and are randomized 1:1 to receive either QL1706 in combination with albumin paclitaxel and gemcitabine or to receive QL1706 in combination with albumin paclitaxel, gemcitabine, and bevacizumab in 3-week intervals until protocol-specified treatment termination Event. Subjects will be enrolled in the study and will undergo a safety visit prior to D1 dosing for each treatment cycle, please refer to the trial flow chart. Imaging exams and assessments will be performed every 6 weeks (± 7 days) for the first 24 weeks of treatment and every 9 weeks (± 7 days) thereafter until disease progression, initiation of new antitumor therapy, withdrawal of informed consent, or death, whichever occurs first, as confirmed per RECIST v1.1. Additional imaging and evaluation may be performed at any time during the study if clinically indicated. Subjects will be required to complete safety examinations and imaging assessments at the end of treatment, followed by a safety visit and follow-up until 90 days after the last dose of QL1706 or 30 days after the last dose of other investigational agents, whichever is longer. For subjects who end treatment with non-RECIST v1.1 criteria for disease progression, imaging should be continued to assess time to tumor progression. Survival follow-up is performed after the safety visit, every 60 days (±7 days), to collect and record the subject's survival status and subsequent antitumor therapy. The study used ORR as the primary endpoint and was planned to enroll 50 subjects, 25 in the QL1706 combined albumin paclitaxel and gemcitabine group and 25 in the QL1706 combined albumin paclitaxel and gemcitabine combined bevacizumab group.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 50
• Est. completion date: April 15, 2026
• Est. primary completion date: April 15, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Subjects voluntarily participate in this study, sign the informed consent form;

2. Age =18 years and =75 years;

3. Histologically or cytologically confirmed pancreatic ductal adenocarcinoma or adenocarcinoma.

4. Patients have not received prior systemic therapy for unresectable locally advanced or metastatic pancreatic cancer;

5. At least one measurable lesion according to RECIST 1.1 criteria;

6. ECOG Performance Status 0-1;

7. Estimated life expectancy =3 months;

8. Adequate major organ function (no medication for blood component, cell growth factor correction therapy is allowed within 14 days before randomization);

9. Women of child-bearing potential must agree to use a reliable, effective method of contraception from the time they provide informed consent until at least 120 days after the last dose of study drug is administered. HCG test must be negative. And must be non-lactating;

10. Male participants whose partner is a woman of child-bearing potential must agree to use a reliable, effective method of contraception from the time they sign an informed consent form until at least 120 days after the last dose of study drug is administered. Male subjects also have to agree not to donate sperm during the same period.

Exclusion Criteria:

1. Histologically or cytologically confirmed other pathological types, such as acinar cell carcinoma, pancreatic neuroendocrine neoplasms or pancreatoblastoma.

2. Patients with other malignant tumors within 5 years, except localized tumor that has been cured;

3. Known active or untreated brain metastases, meningeal metastases, spinal cord compression or leptomeningeal disease.

4. Patients with a history of life-threatening bleeding or a definite risk of bleeding within 6 months before randomization;

5. Has undergone major trauma or surgical treatment within 28 days before randomization or is expected to undergo major surgical treatment during the study period;

6. Poorly controlled hypertension (systolic blood pressure =140 mmHg and/or diastolic blood pressure =90 mmHg) ;or have a history of hypertensive crisis or hypertensive encephalopathy;

7. Thrombotic or embolic events, such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, pulmonary embolism, etc., occurred within 6 months before randomization;

8. Patients who receive any prior treatments targeting the mechanism of tumor immunity, such as immune checkpoint blockades, immune checkpoint agonists, immune cell therapy, etc.

9. Active autoimmune disease requiring systemic treatment within 2 years before randomization, or autoimmune diseases that may relapse or require scheduled treatment judged by the investigator;

10. Subjects with active hepatitis B or C;

11. Patients with a known history of immunodeficiency or HIV positive;

12. The investigator assessed that it is not appropriate to participate in the study.

Related Conditions & MeSH terms

• Pancreatic Cancer
• Pancreatic Neoplasms

Intervention

Drug:
• QL1706
QL1706 5mg/kg,IV,D1, Q3W
• Nab-paclitaxel
Nab-paclitaxel, 125mg/m2,IV,D1?8, Q3W
• Gemcitabine
gemcitabine,1000mg/m2,IV,D1?8;Q3W.
• Bevacizumab
bevacizumab, 7.5mg/kg,IV,D1;Q3W.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Fudan University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective response rate (ORR)	ORR is defined as the percentage of subjects with complete response (CR) or partial response (PR) by investigator assessment per RECIST criteria, version 1.1.	up to approximately 1 years
Secondary	Disease control rate (DCR)	DCR was defined as the percentage of patients who have achieved complete response (CR), partial response (PR) and stable disease (SD).	up to approximately 1 years
Secondary	Duration of Response (DoR)	Response will be determined by investigator using RECIST 1.1.	up to approximately 1 years
Secondary	Time to response(TTR)	Response will be determined by investigator using RECIST 1.1.	up to approximately 1 years
Secondary	Progression-free survival (PFS)	PFS is defined as the time from randomization until the date of first occurrence of investigator-assessed radiological disease progression or death due to any cause, whichever came first.	up to approximately 1 years
Secondary	Overall survival(OS)	OS is defined as the time from the date of randomization to the date of death due to any cause.	up to approximately 1 years
Secondary	Adverse Events	AE assessed by NCI-CTCAE v5.0.	up to approximately 1 years